Curaleaf Holdings (CURLF) FCF Margin (2019 - 2024)
Curaleaf Holdings (CURLF) posted quarterly FCF Margin of 10.12% for Q4 2024, up 1097726.0% year-on-year from N/an in Q1 2024, and down 147.67% on a QoQ basis from 21.23% in Q3 2024.
Curaleaf Holdings (CURLF) FCF Margin (2019 - 2024) Analysis & Trends
Curaleaf Holdings (CURLF) has reported FCF Margin for 6 consecutive years, with 10.12% the latest figure, recorded in Q4 2024.
- Quarterly FCF Margin rose 1097726.0% year-over-year to 10.12% in Q4 2024, while the trailing twelve-month figure through Sep 2025 was 2.58% (down 1299.0% YoY) and the FY2025 annual result came in at 10.64%, down 48.0% from the prior year.
- FCF Margin fell to 10.12% in Q4 2024 per CURLF's latest filing, from 21.23% in the prior quarter.
- Over the last five years, FCF Margin for CURLF reached as high as 12915.87% in Q1 2024 and fell as low as 12767.93% in Q2 2024.
- A 5-year average of 566.96% and a median of 10.35% in 2020 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin sank 1092868 bps — and 2024, when it surged 1097726 bps.
- Year by year, FCF Margin stood at 77.33% in 2020, then surged by 110 bps to 7.71% in 2021, then slumped by 861 bps to 58.7% in 2022, then plunged by 18619 bps to 10987.38% in 2023, then soared by 100 bps to 10.12% in 2024.
- According to Business Quant data, FCF Margin over the past three periods registered 10.12%, 21.23%, and 12767.93% for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -5.22% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 12.86% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -5.35% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 46.54% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 9.93% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 17.73% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.77% |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -10.12% |
| Sep 30, 2024 | 21.23% |
| Jun 30, 2024 | -12,767.93% |
| Mar 31, 2024 | 12,915.87% |
| Dec 31, 2023 | -10,987.38% |
| Sep 30, 2023 | 18.66% |
| Jun 30, 2023 | -2,348.75% |
| Mar 31, 2023 | 2,373.74% |
| Dec 31, 2022 | -58.70% |
| Sep 30, 2022 | 13.55% |
| Jun 30, 2022 | -11.31% |
| Mar 31, 2022 | 28.03% |
| Dec 31, 2021 | 7.71% |
| Sep 30, 2021 | 30.37% |
| Jun 30, 2021 | -10.05% |
| Dec 31, 2020 | -77.33% |
| Sep 30, 2020 | 10.35% |
| Jun 30, 2020 | 52.49% |
| Mar 31, 2020 | 27.32% |
| Dec 31, 2019 | -289.58% |